Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The purpose of this trial is to evaluate the efficacy and safety of subcutaneous secukinumab 300 mg compared to placebo, in combination with standard of care therapy (SoC), in subjects with active lupus nephritis (ISN/RPS Class III or IV, with or without co-existing class V features).
Epistemonikos ID: 9744df61d28edb6b23fb2f767b928fa7ffabe131
First added on: May 06, 2024